Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 4Phase 1/2 3Phase 1 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Renal Cell 6Kidney Neoplasms 4Ovarian Neoplasms 1Neoplasms 1Kidney Diseases 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Pancreatic Ductal 1

Interventions

Interferon-alpha 7aldesleukin 6Sunitinib 6Radiotherapy 5Nivolumab 5Doxorubicin 5Vincristine 4Ipilimumab 4Filgrastim 4Dactinomycin 4Chemotherapy, Adjuvant 4Axitinib 4cabozantinib 3Sorafenib 3Everolimus 3Etoposide 3Cyclophosphamide 3temsirolimus 2pembrolizumab 2Ifosfamide 2G250 monoclonal antibody 2Fluorouracil 2Carboplatin 2Bevacizumab 2vitespin 1shark cartilage extract 1pazopanib 1lenvatinib 1glutamic acid diethyl ester 1cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Kidney Neoplasms × Axitinib × Clear all
NCT02684006 2025-07-30

JAVELIN Renal 101

Pfizer

Phase 3 Completed
886 enrolled 37 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT06364631 2025-01-16

CARE1

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting
1,250 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00920816 2022-05-06

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Pfizer

Phase 3 Completed
492 enrolled 17 charts
Genitourinary

Kidney Neoplasms

NCT00678392 2019-01-09

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Pfizer

Phase 3 Completed
723 enrolled 15 charts
Genitourinary

Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡